Encounter for screening for malignant neoplasm of ovary
ICD-10 Z12.73 is a billable code used to indicate a diagnosis of encounter for screening for malignant neoplasm of ovary.
Z12.73 is used to indicate an encounter for screening for malignant neoplasm of the ovary. This code is crucial for preventive health measures, particularly for women at higher risk of ovarian cancer due to family history or genetic predispositions such as BRCA mutations. Screening can include pelvic examinations, transvaginal ultrasounds, and CA-125 blood tests. Social determinants of health, such as access to healthcare, socioeconomic status, and education, significantly influence the likelihood of women receiving timely screenings. Preventive care is essential in identifying potential malignancies early, which can lead to better outcomes. Regular screenings can help in early detection, thus reducing morbidity and mortality associated with ovarian cancer. Documentation must reflect the patient's risk factors, the type of screening performed, and any follow-up care required.
Document patient history, risk factors, and details of the screening performed.
Routine checkups where screening for ovarian cancer is indicated based on risk factors.
Consider social determinants such as access to care and education about ovarian cancer risks.
Population-level data on screening rates and outcomes.
Community health initiatives aimed at increasing awareness and screening for ovarian cancer.
Focus on tracking health disparities and access to preventive services.
Used in conjunction with Z12.73 during a comprehensive women's health screening visit.
Document the type of screening performed and results.
Primary care providers should ensure comprehensive documentation of all screenings.
Ordered for patients at high risk for ovarian cancer.
Document the indication for the ultrasound and any findings.
Public health initiatives may track the use of this procedure in screening programs.
Z12.73 should be used during encounters specifically for screening for ovarian cancer, particularly in patients with risk factors such as family history or genetic predispositions.
